BTK and B-cell chronic lymphocytic leukemia: The potential for BTK inhibitors to block inflammatory cytokine release was observed in patients with chronic lymphocytic leukemia (CLL), Waldenström macroglobulinemia (WM), and chronic graft-versus-host disease, and involved many of the proinflammatory and chemoattractant cytokines found elevated in the plasma of patients with SARS-CoV-2 (13–17).